Valiant Laboratories IPO: Profitable Pharmaceutical Investment Opportunity 2023

Valiant Laboratories IPO: Profitable Pharmaceutical Investment Opportunity 2023
Rate this post

Valiant Laboratories IPO Overview:

The Valiant Laboratories IPO is creating a buzz in the investment market, scheduled to open for subscription from September 27, 2023, until October 3, 2023.

Investors can anticipate the allotment results to be finalized on October 5, 2023, with the highly-anticipated listing date set for October 9, 2023.

The IPO offers shares In a price band of ₹133 to ₹140 per share, with a minimum lot size of 105 shares.

Investment Choices:

Retail investors can seize this opportunity with a minimum investment requirement of ₹14,700.

Small High Net Worth Investors (S-HNI) can participate with a minimum of 14 lots (1,470 shares), amounting to ₹205,800.

For Big High Net Worth Investors (B-HNI), the minimum lot size investment is 69 lots (7,245 shares), totaling ₹1,014,300.

Key Players in Valiant Laboratories IPO:

Unistone Capital Pvt Ltd serves as the book running lead manager, ensuring a smooth IPO process. Link Intime India Private Ltd is the registrar for the issue, handling documentation and investor relations.

Financial Performance Highlights Of Valiant Laboratories :

Valiant Laboratories has showcased consistent revenue growth over the years:

Fiscal Year 2021: ₹1,823.69 million

Fiscal Year 2022: ₹2,915.23 million

Fiscal Year 2023: ₹3,338.77 million.

Their profitability is reflected in:

Fiscal Year 2021 Profit After Tax: ₹30.59 Cr .

Fiscal Year 2022 Profit After Tax: ₹27.50 Cr .

Fiscal Year 2023 Profit After Tax: ₹29.00 Cr .

The company’s Net Worth has also demonstrated steady growth:

Fiscal Year 2021 Net Worth: ₹88.58 Cr .

Fiscal Year 2022 Net Worth: ₹71.46 Cr .

Fiscal Year 2023 Net Worth: ₹100.49 Cr

Valiant Laboratories IPO Key Financial Ratios:

P/E Ratio (Price to Earnings): 15.71

Market Cap (Market Capitalization): ₹608.3 Cr ROE (Return on Equity): 33.73%

ROCE (Return on Capital Employed): 22.76% Debt/Equity Ratio: 0.59

EPS (Earnings Per Share): ₹8.91

RoNW (Return on Net Worth): 28.86%

Valiant Laboratories IPO Objectives and Use of Funds:

The IPO aims to raise capital for specific purposes, including:

Investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), for the establishment of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (Proposed Facility).

Funding VASPL’s working capital requirements. Catering to general corporate needs. The Valiant Laboratories IPO presents a unique investment opportunity in the pharmaceutical sector.

With a rich history, impressive financials, and ambitious expansion plans, it’s poised to be a significant player in the market. Don’t miss your chance to be part of this exciting venture.

Valiant Laboratories Limited: Leading Paracetamol API Manufacturer and Innovator in Pharmaceuticals

Company Origin: Established in 1980 as a partnership firm named Bharat Chemicals. Initially, a leading manufacturer of Para Nitro Phenol with applications in drugs, fungicides, and rubber additives.

Pharmaceutical Expansion: Transitioned into the pharmaceutical industry after extensive research and development. Specialized in manufacturing Paracetamol (Active Pharmaceutical Ingredient – API).

Corporate Transformation: Partnership firm transformed into a public limited company known as Valiant Laboratories Limited.

Product Focus: Valiant Laboratories is a leading manufacturer of Paracetamol API/Bulk Drug. Paracetamol API is widely used for treating conditions like headaches, muscle aches, arthritis, backaches, toothaches, colds, and fevers.

Facility and Equipment: State-of-the-art manufacturing facility located at Tarapur Industrial Estate. Equipped with the latest instruments and equipment to meet customer requirements.

API Grades: Offers various grades of the API tailored to customer specifications.

Strategic Location: Conveniently situated approximately 150 Km from Nhava Sheva Port (JNPT). About 110 Km from the company’s registered office in Mumbai, ensuring efficient logistics.

Research and Development: A dedicated team focused on research and development. Continuous exploration of new molecules to enhance the company’s product portfolio and drive growth.

Choose Valiant Laboratories Limited for top-quality Paracetamol API and a commitment to innovation in the pharmaceutical industry.

Valiant Laboratories IPO: Enhancing the Impact of Paracetamol/Acetaminophen in Medical Relief

Paracetamol/Acetaminophen a versatile pharmaceutical ingredient, serves as a potent ally in alleviating a spectrum of discomforts.

Beyond its widespread application in addressing common woes like headaches, muscle aches, arthritis, and toothaches, it emerges as a stalwart companion in the battle against colds and fevers.

Yet, its potential doesn’t stop there; it plays a pivotal role in the intricate choreography of post-surgical pain management, bringing solace to those in need.

This multifaceted compound showcases its prowess in transforming distress into relief across diverse medical landscapes, thanks to the dedication of Valiant Laboratories in ensuring its quality and effectiveness.

Investing in the Valiant Laboratories IPO: A Strategic Opportunity

Impressive Financial Performance: Valiant Laboratories has shown consistent revenue growth and profitability over the years, highlighting its financial strength and future potential.

Pharmaceutical Expertise: Valiant Laboratories specializes in Paracetamol production, a crucial pharmaceutical ingredient with broad applications. Their expertise in this niche sector offers investment opportunities in a high-demand market.

Expansion Initiatives: The IPO proceeds will fund expansion, including the establishment of a specialty chemicals manufacturing facility. This signifies the company’s commitment to growth and diversification.

Favorable Financial Ratios: Key financial ratios such as PE ratio, ROE, ROCE, and Debt/Equity ratio indicate robust financial health and efficient capital management.

Pharmaceutical Sector Promise: The pharmaceutical sector typically enjoys steady demand, and Valiant Laboratories, with its strong product portfolio, is well-positioned to benefit from this market stability.

FAQs About Valiant Laboratories IPO:

How Can I Invest in the Valiant Laboratories IPO?

To invest in the Valiant Laboratories IPO, you can follow the subscription process during the open period from September 27, 2023, to October 3, 2023, through authorized channels.

What is the Minimum Investment Requirement for Retail Investors?

Retail investors can participate with a minimum investment of ₹14,700 in the Valiant Laboratories IPO.

What Are the Key Financial Ratios of Valiant Laboratories?

The company’s key financial ratios include a P/E Ratio of 15.71, ROE of 33.73%, ROCE of 22.76%, Debt/Equity Ratio of 0.59, and EPS of ₹8.91.

What Are Valiant Laboratories IPO Objectives and Use of Funds?

Valiant Laboratories IPO aims to raise capital for purposes such as investing in its subsidiary for specialty chemicals manufacturing, funding working capital requirements, and addressing general corporate needs.

Where is Valiant Laboratories Located, and What is Its Specialization?

Valiant Laboratories is based in Palghar, Maharashtra, India, and specializes in the manufacturing of Paracetamol, a widely used pharmaceutical ingredient for various medical conditions.

When Will the Allotment Results for the Valiant Laboratories IPO Be Announced?

The allotment results for the Valiant Laboratories IPO are expected to be finalized on October 5, 2023.

What Are the Expansion Plans Mentioned in Valiant Laboratories IPO Objectives?

The IPO funds will be used to establish a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Gujarat. This expansion reflects the company’s growth strategy beyond its existing pharmaceutical focus.

Disclaimer :

The information provided in this blog is for general informational purposes only and should not be considered as professional financial or investment advice. Always conduct thorough research and seek advice from a qualified financial advisor before making any investment decisions. The blog author and publisher are not responsible for any actions taken based on the information provided in this blog. Any reliance on the content is at your own risk. Remember that the financial markets can be volatile, and past performance is not indicative of future results. The company mentioned in the blog may have undergone changes or developments that are not reflected here. Please verify the information with credible sources before making any financial decisions.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
5 large-cap stock ideas Escorts Limited A Mid Cap Stock : 197.72% Return Potential Hybrid Mutual Fund : which give you high returns at moderate risk 3 stocks of Nifty Smallcap 50: Giving high returns in the short term 5 Key Benefits of Investing In Cipla Stock Highlights for 5 large cap companies’ performance in Q1 FY2023-24 What is happening with Tata Power? is now the Time to Buy? FII stake is increase in 10 mid cap stocks : Chance to invest